Piramal Pharma Limited
Indian pharmaceutical company providing contract development and manufacturing services, critical care hospital generics, and consumer healthcare products globally.
Company Type
public
Founded
1988
Headquarters
Mumbai, India
Stock
NSE: PPLPHARMA
About Piramal Pharma Limited
Who owns Piramal Pharma?
Piramal Pharma is publicly traded on NSE (PPLPHARMA) and BSE (543635). The Piramal Group (Ajay Piramal family) is the controlling shareholder. Carlyle Group holds approximately 15% following its 2020 investment.
Piramal Pharma is publicly traded on NSE (PPLPHARMA) and BSE (543635). The Piramal Group (Ajay Piramal family) is the controlling shareholder. Carlyle Group holds approximately 15% following its 2020 investment.
What does Piramal Pharma do?
Piramal Pharma provides contract development and manufacturing (CDMO) services to global pharmaceutical companies, manufactures inhalational anesthetics and hospital generics (Piramal Critical Care), and sells consumer healthcare products in India (Lacto Calamine, i-pill, Saridon).
Piramal Pharma provides contract development and manufacturing (CDMO) services to global pharmaceutical companies, manufactures inhalational anesthetics and hospital generics (Piramal Critical Care), and sells consumer healthcare products in India (Lacto Calamine, i-pill, Saridon).
Is Piramal Pharma publicly traded?
Yes, Piramal Pharma is listed on NSE (PPLPHARMA) and BSE (543635). The company was demerged from Piramal Enterprises and listed in October 2022.
Yes, Piramal Pharma is listed on NSE (PPLPHARMA) and BSE (543635). The company was demerged from Piramal Enterprises and listed in October 2022.
What is Piramal Pharma Solutions?
Piramal Pharma Solutions is the company's CDMO business, providing integrated contract development and manufacturing services to global pharmaceutical companies across the drug development lifecycle.
Piramal Pharma Solutions is the company's CDMO business, providing integrated contract development and manufacturing services to global pharmaceutical companies across the drug development lifecycle.
What consumer brands does Piramal Pharma own?
Piramal Pharma's consumer healthcare brands in India include Lacto Calamine (skin care), i-pill (emergency contraceptive), Saridon (headache relief), Littles (baby care), and Naturolax (laxative).
Piramal Pharma's consumer healthcare brands in India include Lacto Calamine (skin care), i-pill (emergency contraceptive), Saridon (headache relief), Littles (baby care), and Naturolax (laxative).
History of Piramal Pharma Limited
Piramal Pharma's origins trace to 1988 when Ajay Piramal's Piramal Group acquired Nicholas Laboratories India Limited, a pharmaceutical company. This acquisition marked the Piramal Group's entry into the pharmaceutical industry.
In 1993, Piramal Enterprises acquired Roche Products (India) Ltd from Hoffmann-La Roche, which was later renamed Piramal Healthcare Ltd. This acquisition added significant pharmaceutical manufacturing capabilities.
Piramal Healthcare expanded its CDMO capabilities through the acquisition of Hoechst Research Centre in Mulund (2000) and other facilities. The company built expertise in active pharmaceutical ingredient (API) manufacturing and drug formulation development.
In 2010, Piramal Healthcare made a landmark strategic decision, selling its domestic formulations business to Abbott Laboratories for approximately $3.72 billion. This was one of the largest pharmaceutical deals in Indian history. The sale allowed Piramal to focus on higher-margin CDMO services, critical care, and consumer healthcare.
Following the Abbott sale, Piramal expanded its CDMO business through acquisitions:
- **Decision Point** (2012): Acquired a US-based pharmaceutical consulting firm.
- **Coldstream Laboratories** (2012): Acquired a US-based CDMO.
- **Ash Stevens** (2012): Acquired a US-based API manufacturer.
- **Torcan Chemical** (2013): Acquired a Canadian API manufacturer.
In 2020, Carlyle Group invested approximately $490 million in Piramal Pharma for approximately 20% stake, providing capital for growth and validating the company's CDMO strategy.
In 2022, Piramal Enterprises was restructured, with the pharmaceutical and healthcare operations demerged as Piramal Pharma Limited and the financial services operations continuing as Piramal Enterprises. Piramal Pharma was listed on NSE and BSE in October 2022.
For fiscal year 2024 (ending March 2024), Piramal Pharma reported revenue of approximately 82 billion INR.
Brands Owned by Piramal Pharma Limited
Piramal Pharma Limited owns 3 brands in our database.
Piramal Consumer Healthcare
Owned by Piramal Pharma Limited
Over-the-counter consumer healthcare products company offering skincare, wellness, pain relief, and personal care solutions in India.
consumer-healthcareotc-productsskincare
Piramal Critical Care
Owned by Piramal Pharma Limited
Global leader in inhalational anesthetics and complex hospital generics providing critical care pharmaceutical products to healthcare facilities worldwide.
anestheticshospital-genericscritical-care
Piramal Pharma Solutions
Owned by Piramal Pharma Limited
Global contract development and manufacturing organization providing integrated CDMO services across the drug lifecycle for pharmaceutical companies.
cdmocontract-manufacturingdrug-development
Shop Piramal Pharma Limited Brands
Disclosure: We may earn commission from purchases
Stock Information
Piramal Pharma Limited Ownership: Pros & Cons
Advantages
- +Leading global CDMO with integrated capabilities from drug discovery to commercial manufacturing
- +17 manufacturing facilities in regulated markets (US, UK, Europe, India) provide competitive advantage
- +World-leading position in inhalational anesthetics through Piramal Critical Care
- +Carlyle Group's investment validates CDMO strategy and provides financial backing
- +Diversified revenue across CDMO, hospital generics, and consumer healthcare
Considerations
- -CDMO business is dependent on pharmaceutical industry R&D spending cycles
- -Regulatory compliance across US FDA, UK MHRA, EMA, and CDSCO creates complexity
- -Competition from larger global CDMOs (Lonza, Catalent, Thermo Fisher/Patheon)
- -Consumer healthcare business is primarily India-focused, limiting international diversification
- -Currency risk from revenues in USD/EUR versus costs in INR
Frequently Asked Questions About Piramal Pharma Limited
Who owns Piramal Pharma?
Piramal Pharma is publicly traded on NSE (PPLPHARMA) and BSE (543635). The Piramal Group (Ajay Piramal family) is the controlling shareholder. Carlyle Group holds approximately 15% following its 2020 investment.
What does Piramal Pharma do?
Piramal Pharma provides contract development and manufacturing (CDMO) services to global pharmaceutical companies, manufactures inhalational anesthetics and hospital generics (Piramal Critical Care), and sells consumer healthcare products in India (Lacto Calamine, i-pill, Saridon).
Is Piramal Pharma publicly traded?
Yes, Piramal Pharma is listed on NSE (PPLPHARMA) and BSE (543635). The company was demerged from Piramal Enterprises and listed in October 2022.
What is Piramal Pharma Solutions?
Piramal Pharma Solutions is the company's CDMO business, providing integrated contract development and manufacturing services to global pharmaceutical companies across the drug development lifecycle.
What consumer brands does Piramal Pharma own?
Piramal Pharma's consumer healthcare brands in India include Lacto Calamine (skin care), i-pill (emergency contraceptive), Saridon (headache relief), Littles (baby care), and Naturolax (laxative).
Jobs at Piramal Pharma Limited
Latest News About Piramal Pharma Limited
Related Articles About Piramal Pharma Limited
View more articles
News & Updates
Monthly M&A Roundup: February 2026 Brand Ownership Changes
From Keurig Dr Pepper's planned split to the Netflix-WBD saga, here is every major brand ownership change and deal in February 2026.
Who Brands StaffFeb 12, 2026
m-and-a-roundupacquisitionsnews
Industry Analysis
The Most Acquired Categories: Tech vs CPG vs Pharma
Which industries see the most brand acquisitions? We compared technology, consumer goods, and pharmaceuticals to find out where the most M&A activity happens and why.
Who Brands StaffFeb 11, 2026
acquisitionsindustry-analysistechnology
Consumer Education
The Truth About 'Made in America' Brand Claims
Many brands market themselves as American-made. But what does that actually mean when the parent company is foreign, the parts come from overseas, and 'assembled in USA' is not the same as 'made in USA'?
Who Brands StaffFeb 11, 2026
made-in-americaconsumer-educationbrand-claims